18 Sep 2018
Posted in Press Release
Regeneron’s supplemental biologics license application of Eylea for the treatment of diabetic retinopathy could slow its downfall, says GlobalData
Following Regeneron’s announcement that the FDA has accepted to review a supplemental biologics license application (sBLA) of Eylea for the treatment of diabetic retinopathy,
Edit Kovalcsik, Managing Analyst at GlobalData, a leading data and analytics company, offers her view on the impact of this indication expansion on the Eylea market;
“Regeneron’s Eylea (aflibercept), a vascular endothelial growth factor (VEGF) inhibitor, is FDA approved for DME, DR in patients with DME, macular edema (ME) following retinal vein occlusion (RVO), as well as for neovascular (wet) age-related macular degeneration (AMD). Following successful Phase III trial demonstrating that Eylea can reverse disease progression in patients with non-proliferative DR without DME, Regeneron is now seeking approval of its blockbuster eye drug encompassing a much wider target among the diabetic patient pool.
‘‘Eylea sales have superseded its rival’s (Lucentis’) global sales since 2015, generating almost twice the sales of Roche/Novartis’ anti-VEGF in 2017; $6.3bn and $3.3bn, respectively. In fact, Eylea dominated global ophthalmology drug sales in 2017, with a market share of approximately 40% share in the ophthalmology space, according to GlobalData’s Report: ‘The Biopharmaceutical Industry in 2017: Highlights by Therapeutic Area’. Eylea’s popularity is partly due to its labelling, which allows for the intravitreal (IVT) injection of the drug in 8-week dosing interval compared to a more frequent 4-week dosing regimen for Lucentis.
“Eylea’s lead position is however about to be threatened by the foreseeable launch of an even less frequently administered anti-VEGF, Novartis’ brolucizumab (RTH258), in 2019 for the treatment of wet AMD. Wet AMD comprised the biggest share of key ophthalmology markets in 2016 and accounted for almost half of all Eylea sales in 2017, according to GlobalData’s reports: ‘The Biopharmaceutical Industry in 2017: Highlights by Therapeutic Area’ and ‘Age-Related Macular Degeneration: Global Drug Forecast and Market Analysis to 2026’.
“While the diagnosed prevalence of DME comprises about 1 million diabetic patients in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan) DR encompassed a much larger patient population of about 9.2 million diagnosed prevalent cases estimated in the 7MM in 2016, according to GlobalData’s report: ‘EpiCast Report: Macular Edema – Epidemiology Forecast to 2026’.
‘‘Undoubtedly, Regeneron’s target population for Eylea will substantially increase with the added indication, which could minimize the anticipated loss of Eylea sales to Novartis’ brolucizumab in the wet AMD space.”
For more information
To gain access to our latest press releases: GlobalData Media Centre
Analysts available for comment. Please contact the GlobalData Press Office:
EMEA & Americas: +44 (0)207 832 4399
Asia-Pacific: +91 40 6616 6809
Notes to Editors
Comments provided by Dr. Edit Kovalcsik, Cardiovascular and Metabolic Diseases Managing Analyst for GlobalData
Information taken from GlobalData’s OpportunityAnalyzer: Endometriosis – Opportunity Analysis and Forecast to 2025
4,000 of the world’s largest companies, including over 70% of FTSE 100 and 60% of Fortune 100 companies, make more timely and better business decisions thanks to GlobalData’s unique data, expert analysis and innovative solutions, all in one platform. GlobalData’s mission is to help our clients decode the future to be more successful and innovative across a range of industries, including the healthcare, consumer, retail, financial, technology and professional services sectors. PR2762